New York, NY -- (SBWIRE) -- 12/22/2014 -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Christine Silverstein as director of investor relations, effective immediately. She will report to Michael Becker, senior vice president of finance and corporate development at Relmada.
"With Christine's corporate communications experience and relationships, she is ideally suited to help effectively share the Relmada story with the investment community," said Sergio Traversa, chief executive officer of Relmada. "As we continue the growth and evolution of the company, she will play a key role in further embedding the perspective of investors into our business."
Ms. Silverstein brings more than 10 years of experience in corporate communications and financial services. Most recently, she served as the vice president of corporate development for PlasmaTech BioPharmaceuticals, Inc. (formerly Access Pharmaceuticals). In this role, she served as the primary point of contact and corporate liaison with security analysts, fund managers and stockbrokers. She also served as Managing Director at SCO Financial Group, a New York based life science financial advisory firm.
Earlier in her career, Ms. Silverstein held senior positions at both The Investor Relations Group and Corporate Profile LLC, two boutique investor and public relations firms based in New York's financial district, where she was responsible for consulting C-level management on capital markets strategies, digital media, banking initiatives, and regulatory issues. She began her career in the financial services industry as a registered representative for Royal Alliance Associates. Christine holds a B.S. from the Peter Tobin College of Business, St. John's University.
"It's an exciting time to be joining Relmada," said Ms. Silverstein. "The Company's compelling and diverse product portfolio, alongside the mission of developing innovations in pain medicine, has me eager to articulate our unique investment case to investors and analysts as the company executes on its business strategy."
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: htttp://www.relmada.com.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.